Catalyst Brief

← Calendar

Readoutin 164d

Xenon Pharmaceuticals Inc. — Azetukalner

Phase 3 primary completion: A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3).

Date
May 2027
Type
Readout
Indication
Major Depressive Disorder

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Xenon Pharmaceuticals Inc.

  1. Jan2027